-
Jan 21, 2026, 10:51 pm78 pts
Ars Technica
In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with standard treatment alone. That's according to Moderna and Merck, the two pharmaceutical companies that have…
Trending Today on Tech News Tube
Tech News Tube is a real time news feed of the latest technology news headlines.
Follow all of the top tech sites in one place, on the web or your mobile device.
Follow all of the top tech sites in one place, on the web or your mobile device.
